NGF   Click here for help

GtoPdb Ligand ID: 5026

Synonyms: beta-nerve growth factor | beta-NGF | Oxervate® | Sentinel®
Approved drug
NGF is an approved drug (EMA (2017), FDA (2018))
Comment: Recombinant NGF (cenegermin, also known as cenegermin-bkbj) is used clinically as a peripherally selective agonist of TrkA and LNGFR. Note that the recombinant peptide is two amino acids shorter than the endogenous peptide, with the carboxy-terminal RA (Arg-Ala) removed.
Species: Human
Click here for help
1. Jeon YH, Lee JY, Kim S. (2012)
Chemical modulators working at pharmacological interface of target proteins.
Bioorg Med Chem, 20 (6): 1893-901. [PMID:22227462]
2. MacDonald L, Torres R, Morra MR, Martin JH, Reinhardt JC. (2011)
High affinity human antibodies to human nerve growth factor.
Patent number: US7988967 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 10/08/2007. Publication date: 02/08/2011.
3. Pons J, Rosenthal A. (2008)
Anti-NGF antibodies and methods using same.
Patent number: US7449616 B2. Assignee: Pfizer Inc.. Priority date: 24/12/2002. Publication date: 11/11/2008.
4. Wild KD Jr, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F. (2009)
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors.
Patent number: US7601818 B2. Assignee: Amgen, Inc., Medarex, Inc.. Priority date: 15/07/2003. Publication date: 13/10/2009.